torcetrapib

(redirected from CETP inhibitor)

torcetrapib

A cholesterol ester transfer protein (CETP) inhibitor drug that has been shown capable of substantially increasing levels of high density lipoprotein (HDL) cholesterol. A major trial of this drug in conjunction with atorvastatin was stopped by Pfizer at the end of 2006.
References in periodicals archive ?
Dr Louise Bowman, the other co-principal investigator of REVEAL, explained: The REVEAL trial recruited around twice as many participants as any other trial of a CETP inhibitor, collected information on double the number of cardiovascular events, and gave CETP treatment for twice as long.
In patients with acute coronary syndrome (ACS), treatment with dalcetrapib, another CETP inhibitor, also significantly raised HDL-C, principally via an increase in ABCA1-mediated cholesterol efflux (15, 49).
stopped a late-stage study of its CETP inhibitor, torcetrapib, in late 2006, when the drag--despite raising good cholesterol levels as intended--was found to increase the risk of death and heart problems in a clinical trial.
Amgen gains itsTA-8995 oral, once-daily CETP inhibitor in development for use in patients with mild dyslipidemia.
The team at Forbion recognized early on the potential of TA-8995, an oral, once-daily CETP inhibitor and helped to found, fund and staff the company, including in-licensing this lead asset from Mitsubishi Tanabe Pharma Corp.
22,23 The CETP inhibitor Anacetrapib has been shown to reduce Lp(a) plasma levels by up to 50%.
Results of another study of a CETP inhibitor, dalcetrapib, were presented at the American Heart Association annual meeting in November 2012 and published simultaneously in the New England Journal of Medicine.
18 November 2010 - US pharmaceutical company Merck and Co Inc (NYSE: MRK) said yesterday that its investigational CETP inhibitor anacetrapib has met safety and efficacy endpoints in patients with coronary heart disease (CHD) in a Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study.
Indeed, the drug company Pfizer, based in New York, is currently testing a CETP inhibitor as a promoter of heart health.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the discontinuation of Roche/Japan Tobacco's dalcetrapib earlier this year leaves Merck's anacetrapib as the front-runner in the novel CETP inhibitor drug class in the dyslipidemia drug market.
The first CETP inhibitor, torcetrapib, proved unsuccessful because it increased levels of aldosterone, a hormone that increases blood pressure.
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.